Sanofi ($SNY) made its fair share of bad headlines in the latter half of 2014, and law firms are hoping that means one thing: plaintiffs for shareholder lawsuits against the French drugmaker. Potential claims focus on an alleged illegal kickback strategy for the company's diabetes franchise, designed to boost sales. More